{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T04:23:44Z","timestamp":1742358224561,"version":"3.40.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation of China (NSFC) programme","award":["No. 82370176"],"award-info":[{"award-number":["No. 82370176"]}]},{"name":"Hubei Province key research and development plan","award":["No. CZKYXM2023036JZ"],"award-info":[{"award-number":["No. CZKYXM2023036JZ"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13907-5","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T10:30:41Z","timestamp":1742293841000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Establishment of CD34\u2009+\u2009hematopoietic stem cell-derived xenograft model of hyperleukocytic acute myeloid leukemia"],"prefix":"10.1186","volume":"25","author":[{"given":"Yanxia","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"issue":"6","key":"13907_CR1","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3324\/haematol.2017.184267","volume":"103","author":"S Bertoli","year":"2018","unstructured":"Bertoli S, Picard M, Berard E, Griessinger E, Larrue C, Mouchel PL, et al. Dexamethasone in hyperleukocytic acute myeloid leukemia. Haematologica. 2018;103(6):988\u201398.","journal-title":"Haematologica"},{"issue":"2","key":"13907_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/17474086.2017.1270754","volume":"10","author":"S Giammarco","year":"2017","unstructured":"Giammarco S, Chiusolo P, Piccirillo N, Di Giovanni A, Metafuni E, Laurenti L, et al. Hyperleukocytosis and leukostasis: management of a medical emergency. Expert Rev Hematol. 2017;10(2):147\u201354.","journal-title":"Expert Rev Hematol"},{"key":"13907_CR3","doi-asserted-by":"publisher","first-page":"9495","DOI":"10.2147\/CMAR.S225123","volume":"11","author":"S Feng","year":"2019","unstructured":"Feng S, Zhou L, Zhang X, Tang B, Zhu X, Liu H, et al. Impact Of ELN Risk Stratification, Induction Chemotherapy Regimens And Hematopoietic Stem Cell Transplantation On Outcomes In Hyperleukocytic Acute Myeloid Leukemia With Initial White Blood Cell Count More Than 100 x 10(9)\/L. Cancer Manag Res. 2019;11:9495\u2013503.","journal-title":"Cancer Manag Res"},{"key":"13907_CR4","doi-asserted-by":"publisher","first-page":"14963","DOI":"10.1038\/srep14963","volume":"5","author":"CA Bretz","year":"2015","unstructured":"Bretz CA, Savage SR, Capozzi ME, Suarez S, Penn JS. NFAT isoforms play distinct roles in TNFalpha-induced retinal leukostasis. Sci Rep. 2015;5:14963.","journal-title":"Sci Rep"},{"issue":"21","key":"13907_CR5","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1182\/blood-2014-10-551507","volume":"125","author":"C Rollig","year":"2015","unstructured":"Rollig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015;125(21):3246\u201352.","journal-title":"Blood"},{"issue":"2","key":"13907_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/hon.2292","volume":"34","author":"AM Ali","year":"2016","unstructured":"Ali AM, Mirrakhimov AE, Abboud CN, Cashen AF. Leukostasis in adult acute hyperleukocytic leukemia: a clinician\u2019s digest. Hematol Oncol. 2016;34(2):69\u201378.","journal-title":"Hematol Oncol"},{"issue":"44","key":"13907_CR7","doi-asserted-by":"publisher","first-page":"e5285","DOI":"10.1097\/MD.0000000000005285","volume":"95","author":"M Stefanski","year":"2016","unstructured":"Stefanski M, Jamis-Dow C, Bayerl M, Desai RJ, Claxton DF, Van de Louw A. Chest radiographic and CT findings in hyperleukocytic acute myeloid leukemia: A retrospective cohort study of 73 patients. Med (Baltim). 2016;95(44):e5285.","journal-title":"Med (Baltim)"},{"issue":"3","key":"13907_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1074\/mcp.M800258-MCP200","volume":"8","author":"C Pan","year":"2009","unstructured":"Pan C, Kumar C, Bohl S, Klingmueller U, Mann M. Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell type-specific functions. Mol Cell Proteom. 2009;8(3):443\u201350.","journal-title":"Mol Cell Proteom"},{"issue":"10","key":"13907_CR9","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1038\/leu.2017.46","volume":"31","author":"A Chaturvedi","year":"2017","unstructured":"Chaturvedi A, Herbst L, Pusch S, Klett L, Goparaju R, Stichel D, et al. Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. Leukemia. 2017;31(10):2020\u20138.","journal-title":"Leukemia"},{"key":"13907_CR10","doi-asserted-by":"crossref","unstructured":"Okada S, Vaeteewoottacharn K, Kariya R. Application of highly immunocompromised mice for the establishment of Patient-Derived xenograft (PDX). Models Cells. 2019;8(8).","DOI":"10.3390\/cells8080889"},{"issue":"3","key":"13907_CR11","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1096\/fj.201700740R","volume":"32","author":"M Wang","year":"2018","unstructured":"Wang M, Yao LC, Cheng M, Cai D, Martinek J, Pan CX, et al. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J. 2018;32(3):1537\u201349.","journal-title":"FASEB J"},{"issue":"6","key":"13907_CR12","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3324\/haematol.2018.193847","volume":"103","author":"E Griessinger","year":"2018","unstructured":"Griessinger E, Andreeff M. NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no. Haematologica. 2018;103(6):921\u20133.","journal-title":"Haematologica"},{"issue":"23","key":"13907_CR13","doi-asserted-by":"publisher","first-page":"4842","DOI":"10.1182\/bloodadvances.2020003958","volume":"5","author":"R de la D\u00edaz","year":"2021","unstructured":"de la D\u00edaz R, Velasco-Hernandez T, Guti\u00e9rrez-Ag\u00fcera F, et al. Engraftment characterization of risk-stratified AML in NSGS mice. Blood Adv. 2021;5(23):4842\u201354.","journal-title":"Blood Adv"},{"key":"13907_CR14","doi-asserted-by":"crossref","unstructured":"Almosailleakh M, Schwaller J. Murine models of acute myeloid leukaemia. Int J Mol Sci. 2019;20(2).","DOI":"10.3390\/ijms20020453"},{"issue":"1","key":"13907_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41374-019-0298-6","volume":"100","author":"C Maletzki","year":"2020","unstructured":"Maletzki C, Bock S, Fruh P, Macius K, Witt A, Prall F, et al. NSG mice as hosts for oncological precision medicine. Lab Invest. 2020;100(1):27\u201337.","journal-title":"Lab Invest"},{"issue":"1","key":"13907_CR16","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41598-017-17534-4","volume":"8","author":"Y Jin","year":"2018","unstructured":"Jin Y, Guo S, Cui Q, Chen S, Liu X, Wei Y, et al. A hospital based retrospective study of factors influencing therapeutic leukapheresis in patients presenting with hyperleukocytic leukaemia. Sci Rep. 2018;8(1):294.","journal-title":"Sci Rep"},{"issue":"10","key":"13907_CR17","doi-asserted-by":"publisher","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","volume":"174","author":"LD Shultz","year":"2005","unstructured":"Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, et al. Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R gamma null mice engrafted with mobilized human Hemopoietic stem cells. J Immunol. 2005;174(10):6477\u201389.","journal-title":"J Immunol"},{"issue":"2","key":"13907_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1365-2249.2011.04462.x","volume":"166","author":"L Covassin","year":"2011","unstructured":"Covassin L, Laning J, Abdi R, Langevin DL, Phillips NE, Shultz LD, et al. Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rgamma(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease. Clin Exp Immunol. 2011;166(2):269\u201380.","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"13907_CR19","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1038\/leu.2014.128","volume":"28","author":"SJ Busfield","year":"2014","unstructured":"Busfield SJ, Biondo M, Wong M, Ramshaw HS, Lee EM, Ghosh S, et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia. 2014;28(11):2213\u201321.","journal-title":"Leukemia"},{"issue":"4","key":"13907_CR20","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1182\/blood-2014-03-564401","volume":"124","author":"MF Martelli","year":"2014","unstructured":"Martelli MF, Di Ianni M, Ruggeri L, Falzetti F, Carotti A, Terenzi A, et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood. 2014;124(4):638\u201344.","journal-title":"Blood"},{"issue":"1","key":"13907_CR21","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1186\/s12885-015-1844-2","volume":"15","author":"S Dong","year":"2015","unstructured":"Dong S, Chen J. SUMOylation of sPRDM16 promotes the progression of acute myeloid leukemia. BMC Cancer. 2015;15(1):893.","journal-title":"BMC Cancer"},{"issue":"4","key":"13907_CR22","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3324\/haematol.2018.191569","volume":"104","author":"E Demmerath","year":"2019","unstructured":"Demmerath E, Bohler S, Kunze M, Erlacher M. In vitro and in vivo evaluation of possible pro-survival activities of PGE2, EGF, TPO and FLT3L on human hematopoiesis. Haematologica. 2019;104(4):669\u201377.","journal-title":"Haematologica"},{"issue":"6","key":"13907_CR23","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1182\/blood.2019001282","volume":"134","author":"X He","year":"2019","unstructured":"He X, Zhu Y, Lin Y, Li M, Du J, Dong H, et al. PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD\u2009+\u2009acute myeloid leukemia. Blood. 2019;134(6):548\u201360.","journal-title":"Blood"},{"key":"13907_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3389\/fonc.2016.00162","volume":"6","author":"A Gopalakrishnapillai","year":"2016","unstructured":"Gopalakrishnapillai A, Kolb EA, Dhanan P, Bojja AS, Mason RW, Corao D, et al. Generation of pediatric leukemia xenograft models in NSG-B2m mice: comparison with NOD\/SCID mice. Front Oncol. 2016;6:162.","journal-title":"Front Oncol"},{"issue":"10","key":"13907_CR25","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1182\/blood-2016-08-734798","volume":"129","author":"MS Shafat","year":"2017","unstructured":"Shafat MS, Oellerich T, Mohr S, Robinson SD, Edwards DR, Marlein CR, et al. Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment. Blood. 2017;129(10):1320\u201332.","journal-title":"Blood"},{"key":"13907_CR26","doi-asserted-by":"crossref","unstructured":"Lu L, Wang YY, Zhang JL, Li DG, Meng AM. p38 MAPK inhibitor insufficiently attenuates HSC senescence administered Long-Term after 6 Gy total body irradiation in mice. Int J Mol Sci 2016;17(6).","DOI":"10.3390\/ijms17060905"},{"issue":"1","key":"13907_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/08923973.2017.1392564","volume":"40","author":"C Sun","year":"2018","unstructured":"Sun C, Yang J, Pan L, Guo N, Li B, Yao J, et al. Improvement of Icaritin on hematopoietic function in cyclophosphamide-induced myelosuppression mice. Immunopharmacol Immunotoxicol. 2018;40(1):25\u201334.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"5\u20136","key":"13907_CR28","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1159\/000449228","volume":"98","author":"Y Chisaki","year":"2016","unstructured":"Chisaki Y, Terada T, Yano Y. Population pharmacodynamic model for bayesian prediction of myelosuppression profiles based on routine clinical data after gemcitabine and carboplatin treatment. Pharmacology. 2016;98(5\u20136):284\u201393.","journal-title":"Pharmacology"},{"issue":"1","key":"13907_CR29","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s13046-018-0948-3","volume":"37","author":"Y Jin","year":"2018","unstructured":"Jin Y, Yang Q, Liang L, Ding L, Liang Y, Zhang D, et al. Compound Kushen injection suppresses human acute myeloid leukaemia by regulating the Prdxs\/ROS\/Trx1 signalling pathway. J Exp Clin Cancer Res. 2018;37(1):277.","journal-title":"J Exp Clin Cancer Res"},{"key":"13907_CR30","doi-asserted-by":"publisher","first-page":"116329","DOI":"10.1016\/j.carbpol.2020.116329","volume":"240","author":"Y Jin","year":"2020","unstructured":"Jin Y, Cai L, Yang Q, Luo Z, Liang L, Liang Y, et al. Anti-leukemia activities of selenium nanoparticles embedded in nanotube consisted of triple-helix beta-d-glucan. Carbohydr Polym. 2020;240:116329.","journal-title":"Carbohydr Polym"},{"key":"13907_CR31","doi-asserted-by":"publisher","first-page":"1295984","DOI":"10.1155\/2020\/1295984","volume":"2020","author":"D Zhang","year":"2020","unstructured":"Zhang D, Luo Z, Jin Y, Chen Y, Yang T, Yang Q, et al. Azelaic acid exerts antileukemia effects against acute myeloid leukemia by regulating the Prdxs\/ROS signaling pathway. Oxid Med Cell Longev. 2020;2020:1295984.","journal-title":"Oxid Med Cell Longev"},{"key":"13907_CR32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.freeradbiomed.2019.11.013","volume":"146","author":"D Zhang","year":"2020","unstructured":"Zhang D, Liu Y, Luo Z, Chen Y, Xu A, Liang Y, et al. The novel thioredoxin reductase inhibitor A-Z2 triggers intrinsic apoptosis and shows efficacy in the treatment of acute myeloid leukemia. Free Radic Biol Med. 2020;146:275\u201386.","journal-title":"Free Radic Biol Med"},{"issue":"7","key":"13907_CR33","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00432-018-2652-2","volume":"144","author":"M Culen","year":"2018","unstructured":"Culen M, Kosarova Z, Jeziskova I, Folta A, Chovancova J, Loja T, et al. The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice. J Cancer Res Clin Oncol. 2018;144(7):1239\u201351.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"13907_CR34","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3324\/haematol.2016.153528","volume":"102","author":"AM Paczulla","year":"2017","unstructured":"Paczulla AM, Dirnhofer S, Konantz M, Medinger M, Salih HR, Rothfelder K, et al. Long-term observation reveals high-frequency engraftment of human acute myeloid leukemia in immunodeficient mice. Haematologica. 2017;102(5):854\u201364.","journal-title":"Haematologica"},{"issue":"1","key":"13907_CR35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ccell.2017.11.012","volume":"33","author":"H Kunimoto","year":"2018","unstructured":"Kunimoto H, Meydan C, Nazir A, Whitfield J, Shank K, Rapaport F, et al. Cooperative epigenetic remodeling by TET2 loss and NRAS mutation drives myeloid transformation and MEK inhibitor sensitivity. Cancer Cell. 2018;33(1):44\u2013e598.","journal-title":"Cancer Cell"},{"issue":"4","key":"13907_CR36","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1172\/JCI129204","volume":"130","author":"L Vago","year":"2020","unstructured":"Vago L, Gojo I. Immune escape and immunotherapy of acute myeloid leukemia. J Clin Invest. 2020;130(4):1552\u201364.","journal-title":"J Clin Invest"},{"issue":"1\u20132","key":"13907_CR37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10555-012-9405-5","volume":"32","author":"GJ Cook","year":"2013","unstructured":"Cook GJ, Pardee TS. Animal models of leukemia: any closer to the real thing? Cancer Metastasis Rev. 2013;32(1\u20132):63\u201376.","journal-title":"Cancer Metastasis Rev"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13907-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13907-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13907-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T10:30:50Z","timestamp":1742293850000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13907-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13907"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13907-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"31 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out followed the Declaration of Helsinki and approved by the Research Ethics Committee of Zhongnan Hospital at Wuhan University (license number: 2017048). Informed written consent was obtained from the HLL patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"499"}}